Key points are not available for this paper at this time.
Abstract: Atopic Dermatitis (AD) is a chronic, inflammatory, and widespread skin disease with heterogeneous manifestations having a significant influence on the lives of youngsters and adults. Atopic Dermatitis prevalence is higher in African-American children compared with European American children, and the interaction between various factors such as genetics, skin barrier dysfunction, and immune abnormalities mainly causes it. Despite various available treatment options for atopic dermatitis, they often fall short in addressing the root cause, prompting patients to seek more effective and enduring solutions. To combat these shortcomings, researchers are focusing on the development of targeted therapy. The development of targeted treatment options involves the utilization of a range of biological agents designed to pinpoint specific components and regulators of inflammatory pathways associated with allergic and inflammatory conditions. Phytochemicals, viz. alkaloids, phenols, carotenoids, and organo-sulphurs, have been utilized in traditional medicine for centuries, which contribute to increased efficacy while minimizing adverse events. The objective of this review is to give information about the epidemiology, pathophysiology, and evolving landscape of targeted therapy for atopic dermatitis, encompassing both biologics and phytochemicals.
Chauhan et al. (Mon,) studied this question.